Philip Morris International Inc. (PMI) Presents at the 2021 Goldman Sachs Global Staples Forum
Philip Morris International (NYSE: PM) CEO Jacek Olczak addressed investors today at the Goldman Sachs Global Staples Forum, focusing on the company's transformation towards a smoke-free future. PMI aims to replace cigarettes with smoke-free alternatives, benefiting smokers and society. The company operates in 66 markets, and as of March 31, 2021, around 14 million adults have switched to its IQOS device. A live webcast of the session is available, alongside slides on PMI's investor relations page.
- 14 million adults have switched to IQOS and stopped smoking.
- PMI's smoke-free products are available in 66 markets.
- FDA has authorized IQOS as a Modified Risk Tobacco Product.
- None.
Regulatory News:
Philip Morris International Inc.’s (NYSE: PM) Chief Executive Officer, Jacek Olczak, addresses investors today at the Goldman Sachs Global Staples Forum.
The presentation and Q&A session will be conducted in a virtual format, beginning at approximately 9:40 a.m. Eastern Time. A live video webcast of the entire PMI session will be available, in a listen-only mode, at www.pmi.com/2021goldmansachs. Presentation slides will be available at www.pmi.com/investors.
An archived copy of the webcast will be available at www.pmi.com/2021goldmansachs until Wednesday, June 16, 2021. The archived webcast can also be accessed on iOS or Android devices by downloading PMI’s free Investor Relations Mobile Application at http://www.pmi.com/irapp.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2021, PMI's smoke-free products are available for sale in 66 markets in key cities or nationwide, and PMI estimates that approximately 14.0 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit and www.pmi.com and www.pmiscience.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005736/en/
FAQ
What key message did Philip Morris International share at the Goldman Sachs Global Staples Forum?
How many adults have switched to IQOS products as of March 31, 2021?
In how many markets does PMI sell its smoke-free products?
What did the FDA authorize regarding IQOS?
Where can I find the archived webcast of the PMI presentation?
